Chairman and CEO of Zenas BioPharma (ZBIO) Buys 36,928 Shares for $769,948

Leon O. Moulder, founder, CEO, and Chairman of Zenas BioPharma (ZBIO), acquired 36,928 shares for $769,948.80 at $20.85 per share on October 7, 2025, through an open-market purchase for a revocable trust, increasing the trust's holdings to over 1.6 million shares. This insider purchase, made at a price approximately 21.5% below the stock's value five days later, marks Moulder's ninth consecutive purchase without any sales over the past year, indicating significant executive confidence in the clinical-stage biopharmaceutical company. Zenas BioPharma, which has a $1.05 billion market cap and recently licensed a Phase 3 multiple sclerosis candidate, is led by Moulder, who previously founded Tesaro, acquired by GSK for $5.1 billion.

Analysis

Leon O. Moulder, Zenas BioPharma's Founder, CEO, and Chairman, executed a significant open-market purchase of 36,928 shares for his revocable trust on October 7, 2025, valued at $769,948.80 at $20.85 per share. This transaction is part of a pattern of nine consecutive insider purchases by Moulder over the past year, with no sales, signaling robust executive confidence in the company's future prospects. The trust's holdings now exceed 1.6 million shares following this acquisition.

The acquisition price of $20.85 per share was approximately 21.5% below the stock's closing price of $26.59 just five days later on October 12, 2025, suggesting Moulder identified a favorable entry point. Despite a TTM net loss of $176.966 million, Zenas BioPharma has experienced a 52.55% 1-year price change, reflecting market optimism for its clinical-stage immunology pipeline.

Zenas BioPharma, currently valued at a $1.05 billion market cap, recently expanded its pipeline by in-licensing orelabrutinib, a Phase 3 multiple sclerosis candidate. Moulder's prior success in founding Tesaro, which was acquired by GSK for $5.1 billion, further underpins the potential for significant value creation or M&A activity for ZBIO, aligning with the overall bullish sentiment.

Key Decisions for Investors

• Investors should closely monitor Zenas BioPharma's clinical trial progress, especially the Phase 3 orelabrutinib candidate, as pipeline advancements will be key value drivers.
• Evaluate the consistent insider buying by CEO Leon Moulder as a strong indicator of management's long-term conviction and potential for future M&A.
• Consider the company's high burn rate and clinical-stage risk profile, balancing the significant growth potential against inherent biotech sector volatility.